SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001479290-18-000108
Filing Date
2018-11-02
Accepted
2018-11-02 16:06:31
Documents
53
Period of Report
2018-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvncq31810q.htm 10-Q 1097477
2 EXHIBIT 31.1 rvnc-q318exhibit311.htm EX-31.1 13583
3 EXHIBIT 31.2 rvnc-q318exhibit312.htm EX-31.2 13483
4 EXHIBIT 32.1 rvnc-q318exhibit321.htm EX-32.1 6250
5 EXHIBIT 32.2 rvnc-q318exhibit322.htm EX-32.2 6419
  Complete submission text file 0001479290-18-000108.txt   4517306

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT rvnc-20180930.xml EX-101.INS 843797
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20180930.xsd EX-101.SCH 33898
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20180930_cal.xml EX-101.CAL 53518
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20180930_def.xml EX-101.DEF 162337
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20180930_lab.xml EX-101.LAB 447347
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20180930_pre.xml EX-101.PRE 260882
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 181157033
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1